DOCSLIB.ORG

Mario Ortega-Thesis- Investigation of Mechanisms of Drug Resistance In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mario Ortega-Thesis- Investigation of Mechanisms of Drug Resistance In University of Bradford eThesis This thesis is hosted in Bradford Scholars – The University of Bradford Open Access repository. Visit the repository for full metadata or to contact the repository team © University of Bradford. This work is licenced for reuse under a Creative Commons Licence. INVESTIGATION OF MECHANISMS OF DRUG RESISTANCE IN COLORECTAL CANCER: A PROTEOMIC AND PHARMACOLOGICAL STUDY USING NEWLY DEVELOPED DRUG-RESISTANT HUMAN CELL LINE SUBCLONES M. ORTEGA DURAN PhD 2017 Investigation of mechanisms of drug resistance in colorectal cancer: a proteomic and pharmacological study using newly developed drug-resistant human cell line subclones Mario Ortega Duran Submitted for the Degree of Doctor of Philosophy Faculty of Life Sciences University of Bradford 2017 Abstract Mario Ortega Duran Investigation of mechanisms of drug resistance in colorectal cancer: a proteomic and pharmacological study using newly developed drug- resistant human cell line subclones Keywords: Colorectal cancer, 5-Fluorouracil, Oxaliplatin, Irinotecan, Drug resistance, Proteomics, SILAC, chemotherapy, protein interactions, chemosensitivity assays Despite therapeutic advances, colorectal cancer still has a 45% mortality rate, and one of the most crucial problems is the development of acquired resistance to treatment with anticancer drugs. Thus the aims of this project are to develop drug-resistant colon cancer cell lines in order to identify mechanisms of resistance for the most commonly drugs used in colorectal cancer: 5-fluorouracil, oxaliplatin, and irinotecan. Following evaluation of drug sensitivity to these agents in an initial panel of eight colorectal cancer cell lines, 3 lines (DLD-1, KM-12 and HT-29) were selected for the development of 5-FU (3 lines), oxaliplatin (2) and irinotecan (1) resistant sublines by continuous drug exposure, with resistance confirmed using the MTT assay. Consistently resistant sublines were subject to a „stable isotope labelling with amino acids in cell culture‟ (SILAC) approach and a MudPIT proteomics strategy, employing 2D LC and Orbitrap Fusion mass spectrometric analysis, to identify novel predictive biomarkers for resistance. An average of 3622 proteins was quantified for each resistant and parent cell line pair, with on average 60-70 proteins up-regulated and 60-70 down-regulated in the drug resistant sublines. The validity of this approach was further confirmed using immunodetection techniques. These studies have provided candidate proteins which can be assessed for their value as predictive biomarkers, or as therapeutic targets for the modulation of acquired drug resistance in colorectal cancer. i Acknowledgements I would like to express my deepest gratitude to my two Ph.D. supervisors: Dr. Steve Shnyder and Dr. Chris Sutton. Without their knowledge, support, guidance, and mentorship, I would never have become the scientist that I am today, and I will be grateful to them forever for that. I wish firstly to thank my main supervisor Dr. Steve Shnyder, for trusting me from the first moment. Thanks for his kindly welcome, and his weekly and constant supporting, patience, advising, and understanding of my professional and personal life. It was a pleasure to share all these issues during three years and a half with you. I am also thankful to Dr. Chris Sutton for his closeness, his support and for all the confidence placed in me. You have been always there whenever I needed advice to discuss any issue. Really, it has been a great pleasure to work with both of you, great professionals and wonderful people. I would like to thank my new in life-brother, Sadr-ul-shaheed for his invaluable spiritual and professional aid and the most important issue, he did always all of that with a smile on his face. I wish to offer my sincerest thanks to The University of Bradford and all ILSR scholarship and postgraduate program members (Dr. Anne Graham, Mrs. Shamim Haider) for their time and guidance. Thanks to all the staff and members at the Institute of Cancer Therapeutics for sharing three very pleasant years. Finally, I would like to express my deepest gratitude to all my beloved family. You have believed in me and offered your unconditional support. Thank you all. ii To my parents, you have been the mirror of my soul and the main source of all values I have received. Thank you for all you have done and especially for the love with which you have done it. You are the reference in my life. You have also been an example of love and constancy in the midst of difficulties. Thank you for the bountiful knowledge and experiences I gained with you, because is something that I will use during the rest of my life. You are the pride of my life, an example of fight, sacrifice, and perseverance. Thank you for showing me that all things in life must be done with love and at its necessary time. To my brother, I always feel you with me, as if you were by my side. Thank you for growing up with me. Thanks for taking part in so many adventures and new discoveries throughout our lives. Together we will share the dreams of the future. A special dedication to the soul of my beloved grandmother, all time invested in this work is the time that I will never share with any of my family members and friends anymore. Thanks to my homeland, my past history and all special people who entered our lives to enrich ourselves. Finally, this is a work is dedicated to all people around the world who are directly or indirectly affected by any form of cancer and which help us to learn more about life than death. To my family, I could never have been writing this today, without your love and support. Thank you. iii Table of Contents 1 General Introduction .................................................................................... 2 1.1 Colorectal Cancer ............................................................................................. 2 1.1.1 Colorectal Cancer Epidemiology ................................................................ 2 1.1.2 Stages of CRC ............................................................................................. 2 1.2 Treatments for CRC: Surgery, radiotherapy, and chemotherapy .............. 5 1.2.1 Surgery ........................................................................................................ 5 1.2.2 Radiotherapy ............................................................................................... 6 1.2.3 Chemotherapy ............................................................................................. 7 1.2.3.1 Common chemotherapeutics used in CRC ........................................ 10 1.2.3.1.1 5-FU................................................................................................ 10 1.2.3.1.2 OXA ............................................................................................... 11 1.2.3.1.3 IRI ................................................................................................... 11 1.3 A review of the known mechanisms of resistance in CRC chemotherapy 12 1.3.1 Known mechanisms of MDR .................................................................... 14 1.3.1.1 Mechanisms of MDR mediated by membrane transporters .............. 14 1.3.1.2 Mechanisms of MDR mediated by autophagy .................................. 17 1.3.1.3 Mechanisms of MDR mediated by polyploidy .................................. 17 1.3.1.4 Mechanisms of MDR mediated by cancer stem cells ........................ 17 1.4 Experimental approaches for identification of novel mechanisms of resistance in CRC ...................................................................................................... 18 1.4.1 Understanding of cancer resistance through genomics ............................. 18 1.4.2 Understanding genomics through proteomics .......................................... 20 1.4.3 Understanding of cancer resistance through proteomics .......................... 21 1.4.3.1 Mutational processes ......................................................................... 21 1.4.3.2 Transcriptional and Post-transcriptional processes ........................... 22 1.4.3.3 Protein alterations modelling chemotherapy resistance .................... 23 1.4.3.4 Proteomics approaches to identify mechanisms of resistance in cancer………….. ................................................................................................. 27 1.4.3.4.1 Proteomics separation approaches .................................................. 29 1.5 Mass spectrometry ......................................................................................... 30 1.5.1 Approaches in quantitative proteomics ..................................................... 33 iv 1.5.2 Multiple reaction monitoring (MRM) and Parallel reaction monitoring (PRM)…….............................................................................................................. 34 1.5.3 Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) .............. 35 1.5.4 Stable Isotope Labelling by Amino acids in Cell culture (SILAC) .......... 36 1.6 Aims & Objectives .......................................................................................... 41 2 Selection of CRC cell lines for use in resistance studies ................................ 43 2.1 Heterogeneity of CRC cell lines .................................................................... 43 2.2 Criteria for selection of a cell line for resistance studies ............................ 44 2.3 Material and Methods ..............................................................................
Load more

Recommended publications
  • A Systematic Benchmark of Nanopore Long Read RNA Sequencing for Transcript Level Analysis in Human Cell Lines
    bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440736; this version posted April 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. A systematic benchmark of Nanopore long read RNA sequencing for transcript level analysis in human cell lines Authors: Ying Chen1, Nadia M. Davidson2,3, Yuk Kei Wan1, Harshil Patel4, Fei Yao1, Hwee Meng Low1, Christopher Hendra1,5, Laura Watten1, Andre Sim1, Chelsea Sawyer4, Viktoriia Iakovleva1,6, Puay Leng Lee1, Lixia Xin1, Hui En Vanessa Ng7, Jia Min Loo1, Xuewen Ong8, Hui Qi Amanda Ng1, Jiaxu Wang1, Wei Qian Casslynn Koh1, Suk Yeah Polly Poon1, Dominik Stanojevic1,9, Hoang-Dai Tran1, Kok Hao Edwin Lim1, Shen Yon Toh10, Philip Andrew Ewels11, Huck-Hui Ng1, N.Gopalakrishna Iyer10,12, Alexandre Thiery13, Wee Joo Chng6,7,14, Leilei Chen7,15, Ramanuj DasGupta1, Mile Sikic1,9, Yun-Shen Chan1, Boon Ooi Patrick Tan1,7,8, Yue Wan1, Wai Leong Tam1,7,16,17, Qiang Yu1, Chiea Chuan Khor1,12,18, Torsten Wüstefeld1,10,14, Ploy N. Pratanwanich1,19,20, Michael I. Love21,22, Wee Siong Sho Goh1, 23, Sarah B. Ng1, Alicia Oshlack2,24, Jonathan Göke1,10*, SG-NEx consortium Affiliations: 1.Genome Institute of Singapore, Singapore, Singapore 2.Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 3.School of BioSciences, The University of Melbourne, Parkville, Victoria, Australia 4.Bioinformatics and Biostatistics, The
    [Show full text]
  • An Investigation Into the Utility of Guilt by Association Machine Learning Algorithms for the Prioritization of Autism Spectrum Disorder Candidate Risk Genes
    An investigation into the utility of guilt by association machine learning algorithms for the prioritization of autism spectrum disorder candidate risk genes by Margot Patricia Rainbow Gunning B.Sc.H, Queen’s University, 2017 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE in The Faculty of Graduate and Postdoctoral Studies (Bioinformatics) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) December 2019 © Margot Patricia Rainbow Gunning, 2019 The following individuals certify that they have read, and recommend to the Faculty of Graduate and Postdoctoral Studies for acceptance, a thesis/dissertation entitled: An investigation into the utility of guilt by association machine learning algorithms for the prioritization of autism spectrum disorder risk genes submitted Margot Patricia Rainbow in partial fulfillment of the requirements by Gunning for the degree of Master of Science in Bioinformatics Examining Committee: Paul Pavlidis, Michael Smith Laboratories/Psychiatry Supervisor Kurt Haas, Cellular and Physiological Sciences Supervisory Committee Member Elodie Portales-Casamar, Clinical Research Informatics Lead, BCCHR Supervisory Committee Member Joerg Gsponer, Biochemistry/Molecular Biology Additional Examiner ii Abstract Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairments in social interaction and communication, and restrictive repetitive behaviours or interests, with extreme phenotypic and genetic heterogeneity. Currently, genetic association studies
    [Show full text]
  • Finale Inauguraldissertation Cla
    Aus dem Interfakultären Institut für Zellbiologie der Universität Tübingen Abteilung Immunologie Kartierung des HLA-Ligandoms der akuten myeloischen Leukämie zur Entwicklung einer therapeutischen Multipeptidvakzine Inaugural–Disseration zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Eberhard Karls Universität zu Tübingen vorgelegt von Berlin, Anne Claudia 2018 Dekan: Professor Dr. med. I. B. Autenrieth 1. Berichterstatter: Prof. Dr. S. Stevanovic 2. Berichterstatter: Privatdozent Dr. A. Yazdi 3. Berichterstatter: Professor Dr. P. Brossart Tag der Disputation: 25/04/2018 Meiner Familie Inhaltsverzeichnis Inhaltsverzeichnis Abbildungsverzeichnis: ............................................................................................................ III Tabellenverzeichnis: .................................................................................................................. V Abkürzungsverzeichnis: ......................................................................................................... VII 1 Einleitung ............................................................................................................................ 1 1.1 Zusammenspiel zwischen Tumorgenese und Immunsystem ......................................... 1 1.2 Immunologische Grundlagen ....................................................................................... 2 1.2.1 T-Lmphozyten ......................................................................................................... 4 1.2.2 Major
    [Show full text]
  • The University of Chicago the Role of H3k79me2 In
    THE UNIVERSITY OF CHICAGO THE ROLE OF H3K79ME2 IN LEUKEMIA AND ALTERNATIVE SPLICING A DISSERTATION SUBMITTED TO THE FACULTY OF THE DIVISION OF THE BIOLOGICAL SCIENCES AND THE PRITZKER SCHOOL OF MEDICINE IN CANDIDACY FOR THE DEGREE OF DOCTOR OF PHILOSOPHY GRADUATE PROGRAM IN CELL AND MOLECULAR BIOLOGY BY WILLIAM FRANK RICHTER, JR. CHICAGO, ILLINOIS MARCH 2021 Dedicated to my mother, who always supported me in my endeavors and helped spark my interest in science. TABLE OF CONTENTS LIST OF FIGURES ..................................................................................................................... viii LIST OF TABLES .......................................................................................................................... x ACKNOWLEDGEMENTS ........................................................................................................... xi ABSTRACT .................................................................................................................................. xii 1. INTRODUCTION .................................................................................................................. 1 HISTONE POST-TRANSLATIONAL MODIFICATIONS ......................................... 1 DOT1L AND METHYLATION OF LYSINE 79 OF HISTONE H3 ............................ 6 MLL-REARRANGEMENTS AND HISTONE METHYLATION IN LEUKEMIA .. 11 FLT3 LESIONS IN LEUKEMIA ................................................................................. 20 THE ROLES OF HISTONE POST-TRANSLATIONAL MODIFICATIONS IN
    [Show full text]
  • Multi-Omics Integration of Methyltransferase-Like Protein
    www.nature.com/scientificreports OPEN Multi‑omics integration of methyltransferase‑like protein family reveals clinical outcomes and functional signatures in human cancer Ion John Campeanu1,3, Yuanyuan Jiang1,3, Lanxin Liu1, Maksymilian Pilecki1, Alvina Najor1, Era Cobani1, Morenci Manning1, Xiaohong Mary Zhang1,2 & Zeng‑Quan Yang1,2* Human methyltransferase‑like (METTL) proteins transfer methyl groups to nucleic acids, proteins, lipids, and other small molecules, subsequently playing important roles in various cellular processes. In this study, we performed integrated genomic, transcriptomic, proteomic, and clinicopathological analyses of 34 METTLs in a large cohort of primary tumor and cell line data. We identifed a subset of METTL genes, notably METTL1, METTL7B, and NTMT1, with high frequencies of genomic amplifcation and/or up‑regulation at both the mRNA and protein levels in a spectrum of human cancers. Higher METTL1 expression was associated with high‑grade tumors and poor disease prognosis. Loss‑of‑function analysis in tumor cell lines indicated the biological importance of METTL1, an m7G methyltransferase, in cancer cell growth and survival. Furthermore, functional annotation and pathway analysis of METTL1‑associated proteins revealed that, in addition to the METTL1 cofactor WDR4, RNA regulators and DNA packaging complexes may be functionally interconnected with METTL1 in human cancer. Finally, we generated a crystal structure model of the METTL1–WDR4 heterodimeric complex that might aid in understanding the key functional residues. Our results provide new information for further functional study of some METTL alterations in human cancer and might lead to the development of small inhibitors that target cancer‑promoting METTLs. Human methyltransferase-like (METTL) proteins belong to a superfamily of S-adenosyl methionine (SAM)- dependent enzymes that transfer methyl groups to nucleic acids, proteins, lipids, and small molecules 1.
    [Show full text]
  • Genome-Wide CRISPR Screen for PARKIN Regulators Reveals
    Genome-wide CRISPR screen for PARKIN regulators PNAS PLUS reveals transcriptional repression as a determinant of mitophagy Christoph Pottinga, Christophe Crochemorea, Francesca Morettia, Florian Nigscha, Isabel Schmidta, Carole Mannevillea, Walter Carbonea, Judith Knehra, Rowena DeJesusb, Alicia Lindemanb, Rob Maherb, Carsten Russb, Gregory McAllisterb, John S. Reece-Hoyesb, Gregory R. Hoffmanb, Guglielmo Romaa, Matthias Müllera, Andreas W. Sailera, and Stephen B. Helliwella,1 aNovartis Institutes for BioMedical Research, Basel CH 4002, Switzerland; and bNovartis Institutes for BioMedical Research, Cambridge, MA 02139 Edited by Beth Levine, The University of Texas Southwestern, Dallas, TX, and approved November 29, 2017 (received for review June 20, 2017) PARKIN, an E3 ligase mutated in familial Parkinson’s disease, promotes how these proteins are themselves regulated, is important for mitophagy by ubiquitinating mitochondrial proteins for efficient the further understanding of mitophagy and the pathogenesis engagement of the autophagy machinery. Specifically, PARKIN- of Parkinson’s disease. synthesized ubiquitin chains represent targets for the PINK1 kinase Previous studies identified regulators of PINK1/PARKIN- generating phosphoS65-ubiquitin (pUb), which constitutes the mitoph- mediated mitophagy employing RNAi screens with damage- agy signal. Physiological regulation of PARKIN abundance, however, induced mitochondrial translocation of overexpressed GFP- and the impact on pUb accumulation are poorly understood. Using PARKIN as a mitophagy proxy (12–15). These efforts pro- cells designed to discover physiological regulators of PARKIN abun- foundly advanced the understanding of mitophagy regulation; dance, we performed a pooled genome-wide CRISPR/Cas9 knockout however, little is known about how cells set the threshold for screen. Testing identified genes individually resulted in a list of mitophagy to proceed.
    [Show full text]
  • Long Noncoding Rnas Are Critical Regulators of Pancreatic Islet Development and Function
    Long noncoding RNAs are critical regulators of pancreatic islet development and function Ruth A. Singer Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 © 2018 Ruth A. Singer All rights reserved ABSTRACT Long noncoding RNAs are critical regulators of pancreatic islet development and function Ruth A. Singer Diabetes is a complex group of metabolic disorders with genetic, immunological, and environmental etiologies. Decades of diabetes research have elucidated many genetic drivers of normal islet function and dysfunction. Furthermore, genome wide associated studies (GWAS) have discovered that most diabetes susceptibility loci fall outside of coding regions, which suggests a role for noncoding elements in the development of disease. This highlights our incomplete understanding of the islet regulome and suggests the need for detailed functional analyses of noncoding genes to precisely determine their contribution to diabetes susceptibility and disease progression. Transcriptome analyses have revealed that the eukaryotic genome is pervasively transcribed. Strikingly, only a small proportion of the transcriptome is subsequently translated into protein; the majority is made up non-protein coding RNAs (ncRNAs). The most abundant class of these ncRNAs are called long noncoding RNAs (lncRNAs), defined as transcripts longer than 200 nucleotides that lack protein-coding potential. The establishment of lncRNAs, once dismissed as genomic dark matter, as essential gene regulators in many biological processes has redefined the central role for RNA in cells. While evidence suggests a role for lncRNAs in islets and diabetes, in vivo functional characterization of islet lncRNAs is lacking.
    [Show full text]
  • 19-05 Next-MP50 MP Challenge St Malo Report V5
    neXt-MP50 Challenge neXt-MP50 and neXt-CP50 Challenge Updates based on Reports Received by May 11, 2019 Chromosome Number: 2 PIC Leaders: Lydie Lane Major lab members or partners contributing to the neXt-MP50 Challenge Paula Duek (SIB/University of Geneva) Alain Gateau (SIB/University of Geneva) Thibault Robin (SIB/University of Geneva) Frédérique Lisacek (SIB/University of Geneva) Markus Mueller (SIB Lausanne) Amos Bairoch (SIB/University of Geneva) Charlotte Macron (Nestlé Institute of Health Sciences) Antonio Nunez-Galindo (Nestlé Institute of Health Sciences) Loïc Dayon (Nestlé Institute of Health Sciences) Status of the Chromosome “parts list” for your Chromosome: (https://www.nextprot.org/about/protein-existence) There were 130 MP on chr 2 in 2017, now only 90 (71 PE2, 18 PE3 and 1 PE4). A) Titles and authors of papers submitted to the 2019 JPR SI or planned. neXt-MP50 Challenge Progress on Identifying and Characterizing the Human Proteome: 2018-2019 Metrics from the HUPO Human Proteome Project. Omenn GS, Lane L, Overall CM, Corrales FJ, Schwenk JM, Paik YK, Van Eyk JE, Liu S, Snyder M, Baker MS, Pennington S, Deutsch EW, in preparation. neXt-CP50 Challenge Characterization of two newly identified nuclear encoded mitochondrial proteins. Mary C, Duek P, Fkih M'Hamed I, Bairoch A, Lane L, in preparation A Blinded Comparison of Function Annotation of uPE1 Proteins using the I-TASSER/COFACTOR Pipeline and the 2018-2019 Additions to neXtProt. Zhang C, Lane L, Zhang Y, Omenn GS, in preparation. C-HPP 2019-05-11 1 neXt-MP50 Challenge B) Titles and authors of papers published in the 2018 JPR SI.
    [Show full text]